Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 14/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | P4HB | P07237 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899355 | 0.85 | CHRM2 (0.50) | ALDH1A1BLMMAPK1 | |
| SCHEMBL8670380 | 0.85 | LMNA (0.63) | MEN1KMT2AALDH1A1POLBKDM4E | |
| SCHEMBL9897988 | 0.82 | BLM (0.52) | MEN1KMT2AALDH1A1POLBP4HB | |
| SCHEMBL31643319 | 0.80 | KMT2A (0.67) | MEN1KMT2AALDH1A1POLBP4HB | |
| SCHEMBL9928307 | 0.79 | BLM (0.52) | MEN1KMT2AALDH1A1BLMMAPK1 | |
| SCHEMBL9928310 | 0.79 | BLM (0.51) | ALDH1A1BLMMAPK1 | |
| SCHEMBL9231221 | 0.77 | MEN1 (0.47) | MEN1KMT2AALDH1A1POLBP4HB | |
| SCHEMBL14264506 | 0.77 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1POLBP4HB | |
| SCHEMBL3632940 | 0.76 | KMT2A (0.49) | MEN1KMT2AALDH1A1POLBP4HB | |
| SCHEMBL28978286 | 0.76 | ALDH1A1 (0.49) | ALDH1A1BLMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | MEN1 1924/4885KMT2A 3467/4885ALDH1A1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.